Insights

Innovative Target Focus Arrakis Therapeutics specializes in discovering small-molecule medicines that target RNA, including traditionally undruggable targets, opening up new therapeutic opportunities in diseases where current options are limited.

Strategic Industry Collaborations The company has established high-profile partnerships, notably with Amgen Foundation, which could lead to further collaboration opportunities in RNA therapeutics and expand market reach.

Expanding Scientific Frontiers Leading the development of RNA degrader therapeutics positions Arrakis at the forefront of a rapidly growing segment, offering potential sales avenues for novel mechanisms in drug discovery and development.

Funding & Growth Potential With over $113 million in funding and recent revenues estimated between $25M and $50M, Arrakis is poised for growth, indicating an increasing market opportunity for collaborators and investors in cutting-edge RNA therapies.

Emerging Market Leadership By attending major industry conferences and presenting novel RNA-targeted medicines, Arrakis is establishing itself as a key player in the emerging RNA-focused pharmaceutical landscape, signaling sales prospects through industry visibility.

Arrakis Therapeutics Tech Stack

Arrakis Therapeutics uses 8 technology products and services including Cloudflare, MixItUp, jQuery UI, and more. Explore Arrakis Therapeutics's tech stack below.

  • Cloudflare
    Content Management System
  • MixItUp
    Javascript Frameworks
  • jQuery UI
    Javascript Libraries
  • Slick
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • Microsoft Exchange
    Storage
  • Google Analytics
    Web Analytics
  • jQuery Waypoints
    Web Tools And Plugins

Media & News

Arrakis Therapeutics's Email Address Formats

Arrakis Therapeutics uses at least 1 format(s):
Arrakis Therapeutics Email FormatsExamplePercentage
FLast@arrakistx.comJDoe@arrakistx.com
93%
Last@arrakistx.comDoe@arrakistx.com
5%
FMLast@arrakistx.comJMDoe@arrakistx.com
1%
FirLast@arrakistx.comJohDoe@arrakistx.com
1%

Frequently Asked Questions

Where is Arrakis Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Arrakis Therapeutics's main headquarters is located at 828 Winter Street Waltham, Massachusetts 02451 United States. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Arrakis Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Arrakis Therapeutics's official website is arrakistx.com and has social profiles on LinkedInCrunchbase.

What is Arrakis Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Arrakis Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Arrakis Therapeutics have currently?

Minus sign iconPlus sign icon
As of March 2026, Arrakis Therapeutics has approximately 65 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: M. G.Coo: H. L.Chief Business Officer: J. M.. Explore Arrakis Therapeutics's employee directory with LeadIQ.

What industry does Arrakis Therapeutics belong to?

Minus sign iconPlus sign icon
Arrakis Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Arrakis Therapeutics use?

Minus sign iconPlus sign icon
Arrakis Therapeutics's tech stack includes CloudflareMixItUpjQuery UISlickMicrosoftMicrosoft ExchangeGoogle AnalyticsjQuery Waypoints.

What is Arrakis Therapeutics's email format?

Minus sign iconPlus sign icon
Arrakis Therapeutics's email format typically follows the pattern of FLast@arrakistx.com. Find more Arrakis Therapeutics email formats with LeadIQ.

How much funding has Arrakis Therapeutics raised to date?

Minus sign iconPlus sign icon
As of March 2026, Arrakis Therapeutics has raised $113M in funding. The last funding round occurred on Apr 01, 2019 for $75M.

When was Arrakis Therapeutics founded?

Minus sign iconPlus sign icon
Arrakis Therapeutics was founded in 2015.

Arrakis Therapeutics

Pharmaceutical ManufacturingMassachusetts, United States51-200 Employees

Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.

We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery.

Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery.  We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients.  Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.

Section iconCompany Overview

Headquarters
828 Winter Street Waltham, Massachusetts 02451 United States
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $113M

    Arrakis Therapeutics has raised a total of $113M of funding over 2 rounds. Their latest funding round was raised on Apr 01, 2019 in the amount of $75Mas a Series B.

  • $25M$50M

    Arrakis Therapeutics's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $113M

    Arrakis Therapeutics has raised a total of $113M of funding over 2 rounds. Their latest funding round was raised on Apr 01, 2019 in the amount of $75Mas a Series B.

  • $25M$50M

    Arrakis Therapeutics's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.